Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Apr;15(2):291-303.
doi: 10.1007/s13311-018-0615-6.

Targeted 5-HT1F Therapies for Migraine

Marta Vila-Pueyo  1
Affiliations
Review

Targeted 5-HT1F Therapies for Migraine

Marta Vila-Pueyo. Neurotherapeutics. 2018 Apr.

Abstract

Migraine is a common neurological disease characterised by the presence of attacks of unilateral, severe head pain accompanied by other symptoms. Although it has been classified as the sixth most disabling disorder, the available therapeutic options to treat this condition have not progressed accordingly. The advance in the development of 5-HT1 receptor agonists for migraine, including 5-HT1B/D and 5-HT1F receptor agonists, has meant a major step forward towards the progression of a better treatment for migraine. Triptans have a limited efficacy, and their effect on vasoconstriction makes them unsafe for patients with cardiovascular and/or cerebrovascular diseases. Therefore, novel effective antimigraine treatments without cardiovascular effects are required, such as selective 5-HT1F receptor agonists (ditans). Lasmiditan has much higher affinity for the 5-HT1F receptor than for the vasoconstrictor 5-HT1B receptor. This has been confirmed in preclinical studies performed to date, where lasmiditan showed no effect on vasoconstriction, and in clinical trials, where healthy individuals and patients did not report cardiac events due to treatment with lasmiditan, although it should be confirmed in larger cohorts. Lasmiditan crosses the blood-brain barrier and may act both centrally and peripherally on 5-HT1F receptors expressed on trigeminal neurons. It is a well-tolerated compound that does not induce major adverse events. Although ongoing phase III clinical trials are needed to confirm its efficacy and safety, lasmiditan might offer an alternative to treat acute migraine with no associated cardiovascular risk. This review will focus on the characterisation of 5-HT1 receptor agonists and their effects as migraine therapies.

Keywords: 5-HT1F; LY334370; LY344864; Lasmiditan; Migraine; Migraine treatment.

PubMed Disclaimer

Conflict of interest statement

The author declares that she has no conflict of interest.

References

    1. ICHD The International Classification of Headache Disorders, 3rd edition (beta version) Cephalalgia. 2013;33(9):629–808. doi: 10.1177/0333102413485658. - DOI - PubMed
    1. Diener HC, Dodick DW. Headache research in 2015: progress in migraine treatment. Lancet Neurol. 2016;15(1):4–5. doi: 10.1016/S1474-4422(15)00341-5. - DOI - PubMed
    1. Sicuteri F. Headache as possible expression of deficiency of brain 5-hydroxytryptamine (central denervation supersensitivity) Headache. 1972;12(2):69–72. doi: 10.1111/j.1526-4610.1972.hed1202069.x. - DOI - PubMed
    1. Pithadia AB, Jain SM. 5-Hydroxytryptamine Receptor Subtypes and their Modulators with Therapeutic Potentials. J Clin Med Res. 2009;1(2):72–80. - PMC - PubMed
    1. Lanfumey L, Hamon M. 5-HT1 receptors. Curr Drug Targets CNS Neurol Disord. 2004;3(1):1–10. doi: 10.2174/1568007043482570. - DOI - PubMed

MeSH terms